Lower-dose semaglutide works
A large Danish real‑world analysis found about ~17% average weight loss when semaglutide was used at roughly one‑third the usual dose combined with behavior change — calling into question high‑dose-only strategies. The study suggests dose + lifestyle synergy may deliver strong results while potentially lowering cost and side effects. x.com/TxUnmask/status/2032812606579159484
The retrospective cohort enrolled 2,694 Danish adults between January 2022 and September 2024 dom-pubs.onlinelibrary.wiley.com. Seventy‑eight percent of participants were women, the mean age was 46.8 years, and the mean BMI was 34.3 kg/m2 dom-pubs.onlinelibrary.wiley.com. Care was delivered through the Embla app, which combined personalised semaglutide dosing with intensive behavioural therapy (nutrition, exercise, CBT) and remote clinician oversight eurekalert.org. The study reports a mean semaglutide dose of 1.08 mg per week (SD 0.54) and participant counts of 1,580 at 26 weeks, 712 at 52 weeks and 465 at 64 weeks dom-pubs.onlinelibrary.wiley.com. By week 64, 98% of participants had achieved at least 5% weight loss and 82% had achieved at least 10% weight loss, with consistent outcomes across baseline BMI classes and dose levels dom-pubs.onlinelibrary.wiley.com. Nationwide Danish prescription data show only about 25% of users filled a 2.4 mg semaglutide prescription in routine care, while the Embla cohort had just 28.8% of participants exceed ~1 mg — a stark contrast with the ~90% escalation to full dose seen in many randomized trials diabetesjournals.org. The results were presented at the European Congress on Obesity (ECO 2025) and the manuscript was accepted in a peer‑review journal with receipt/revision/acceptance dates of 27 June, 19 August and 27 August 2025, respectively; Embla has also highlighted projected GLP‑1 spending trends above $150 billion as part of its U.S. rollout messaging eurekalert.org.
